- English (en)
Anton is a European and Chartered Patent Attorney, and works in our Guildford office. He is a partner in our Chemical and Life Sciences team.
Anton specialises in biotechnology, pharmaceutical, chemical and medical device patent matters. In particular, he has a deep understanding of molecular biology, biochemistry, genetics, genomics & proteomics, therapeutic antibodies, immunology, immuno-oncology, plant biotechnology, peptides, biomarkers, bioinformatics, diagnostics, vaccines, stem cells, formulations, chemical engineering, pharmaceuticals and SPC’s. Anton is especially knowledgeable in patenting vaccines, genome editing techniques, including CRISPR, as well as neurodegenerative disorders (primarily Alzheimer’s disease) and gene therapy inventions.
Anton has gained considerable experience in handling all aspects of patent practice, especially meeting inventors directly, and drafting and prosecuting patent applications before the UKIPO, the EPO and national patent offices. Anton has drafted hundreds of patent applications in the biotechnology, chemical and pharma sectors, and is experienced in managing international patent filing strategies for his clients.
Anton has significant experience of advising clients in relation to patent infringement and validity, freedom-to-operate clearances of third party patents, and providing due diligence opinions. Anton also enjoys complex opposition and appeal work, and regularly attends oral proceedings at the EPO.
Anton works for a broad spectrum of clients, and has extensive experience of working with academic institutions and associated technology transfer departments, university-derived spin-out companies, SME’s, as well as large multinational biotechnology and pharmaceutical companies. He is proactive, and provides his clients with clear, commercially relevant advice. Anton regularly lectures on a variety of IP-related topics, including patenting bioscience inventions.
Anton graduated from Nottingham University with an honours degree in Biochemistry & Genetics. He then attended UMIST where he obtained a master’s degree in Bioreactor Systems & Chemical Engineering, in which his research involved the design and construction of expression vectors for use in S. coelicolor. Anton also holds a PhD in Genetic Engineering, in which his research focused on the genetics of ethanol tolerance and production in the yeast, S. cerevisiae. He also has a certificate in Bioinformatics from Manchester University.
- Fellow of the Chartered Institute of Patent Attorneys
- Member of the European Patent Institute
- European Patent Litigator
- UPC Authorised Representative
Awards and Recognition
- Legal 500 UK (PATMA: Patent Attorneys) – 2024 & 2023
- IAM Strategy 300: The World’s Leading IP Strategists – 2022
“Catrin Petty and Anton Hutter have an excellent understanding of chemistry. It helps in making a robust application for novel small molecules. and in granting and defending patents.” Client Testimonial, Legal 500 UK – 2024
“Anton Hutter [is a] standout partner. [he is an] excellent attorney and also demonstrates commercial pragmatism along with knowledge of IP prosecution.” Client feedback, Legal 500 UK (PATMA: Patent Attorneys) – 2023
Vaccine patent filings – recent trends in this dynamic and fast-moving fieldRead more
The impact of G2/21 on biotech patent drafting – extraordinary claims require extraordinary evidenceRead more
A Changed Landscape for Patents in EuropeRead more
Event summary – IP savvy: what every business needs to know to get the most out of their IPRead more
U.S. Supreme Court Referral: Diverging Approaches To Antibody Epitope Claims Between The EPO and USPTO?Read more
EVENT – IP savvy: what every business needs to know to get the most out of their IPRead more
IAM Strategy 300: The World’s Leading IP Strategists 2022 recognises two Venner Shipley ProfessionalsRead more
IAM Strategy 300: The World’s Leading IP Strategists 2021 recognises two Venner Shipley ProfessionalsRead more
Notice of UK public holiday 31 May 2021Read more
An antidote to antibody patent confusion in EuropeRead more
Venner Shipley ranked in IAM Strategy 300 Global Leaders guideRead more
Allie Elend and Anton Hutter ranked in IAM Strategy 300 Global Leaders guideRead more
Allie Elend and Anton Hutter ranked in the 2020 edition of IAM Strategy 300Read more
COVID-19 and IPRead more
How to get your branding rightRead more
Patentability of methods of treatment and diagnosisRead more
Venner Shipley gene therapy client, Quethera Limited, acquired by Astellas PharmaceuticalsRead more
IP audits: taking stock of your intellectual propertyRead more
CRISPR – the IP battleRead more
Inside IP Spring Summer 2017Read more